Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Arsenic Trioxide in Gemcitabine-Refractory Pancreatic Cancer
NCT00053222Phase 2Completed
- Sponsor
- University of Chicago
- Start
- Feb 2003
- Primary completion
- Jan 2005
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of arsenic trioxide in pancreatic adenocarcinoma (PDAC), sponsored by University of Chicago. Started Feb 2003; status: completed.
02
Drugs
arsenic trioxide
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT00053222.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00053222.